2nd ESTRO Forum 2013 rectum during treatment for prostate immobilization, which positioned the imbedded detectors in direct contact with the anterior rectal wall. Prior to treatment, patients were scanned on the treatment couch of a CT-on-rails Linear Accelerator, which allowed precise localization of the detectors. During the patient treatment, dose information was collected and displayed in real time, providing a visual measure of dose rate and cumulative dose as a function of time. Patient treatment was re-planned with the two detectors contoured on the new CT dataset to calculate the expected cumulative dose to the detectors for that corresponding fraction. The daily recalculated dose was compared to the measurement of the delivered dose for the corresponding fraction. Results: The average deviation between the measured dose and the treatment planning system calculated dose over the 58 measurements after removing 5 outliers was -1.5% with a standard deviation of 4.0%. The minimum deviation observed was 0.26% (calculated dose: 191.8 cGy, measured dose: 191.3 cGy). The maximum observed deviation for a detector positioned in contact with the anterior rectal wall was -8.1% (184.7 cGy versus 169.7 cGy) which could indicate organ motion. Patient in-vivo results are displayed in Table 1 with in-phantom results for comparison. Daily in-vivo results for patient number 2 are displayed in Figure 1 . Due to the real time nature of this detector it was also possible to distinguish the dose delivered by individual beams during treatment.
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Conclusions:
This PSD system has proved to be an excellent in-vivo dosimeter, capable of measuring dose received by a patient with high accuracy as treatment is being delivered. This permits daily monitoring of the dose received by patients. The detector has the potential to detect internal organ motion and is certainly capable of alerting users if the patient is not set up properly on the basis of larger dose deviations (20% or above). Additionally, the detector is non invasive, and can be implemented with no alteration of current treatment practices. 
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Materials and Methods:
Nine patients were included in the study so far (six declined). Besides standard imaging for RT planning (4D computed tomography (CT) and DIBH CT), all patients had three additional imaging sessions including three consecutive DIBH CT at treatment fractions 2, 16 and 31. All DIBHs were visually guided. An optical marker based system was used for respiratory monitoring, enabling comfortable voluntary DIBH. Gating window of 2-3 mm was chosen at individual level, adjusted to each patient's performance, when coaching prior to RT planning. The patients' capability to increase lung volume and to perform repeated DIBH lasting 20 seconds or more throughout the RT course was considered a measure of feasibility. The reproducibility of DIBH level was evaluated as intraand inter-fractional variations in DIBH lung volume and intrafractional changes in tumour position. As changes in tumour position were evaluated by manual registrations, intra-observer uncertainty of the registration process was evaluated as well. Results: Lung volume increased with DIBH compared to free breathing by 60% (range 35-87%; p < 0.0001; paired t-test). There was a slight non-significant trend (p=0.23; paired t-test) towards an increased lung volume at DIBH between the planning CT and the treatment days' DIBH CTs: 4% ± 6% (mean ± SD). No further variations in lung volume were observed throughout the treatment course: changes on days 16 & 31 compared to day 2 were 0% ± 3%. Intra-fractional changes in lung volume were small, 1.1%± 0.8%. Intra-observer uncertainty in tumour registration was small, 0.2 mm ± 0.6mm three-dimensionally (3D). Intra-fractional changes in 3D tumour position were 2.1 mm ± 1.4 mm. No trend was observed throughout the course. Intra-fractional 3D tumour position change exceeded 3 mm in two DIBH CT sets, one patient suffered pneumonia at the time, the other patient had a 2 mm difference in chest excursion between the DIBHs on the particular day. The patients, who refused to enter the protocol (6/15) were on average 10 years older (p=0.014; t-test), which could be a potential bias of the study. Conclusions: DIBH seems feasible and reproducible intra-and interfractionally during a course of NSCLC RT and is well tolerated. We are continuously accruing more patients in the protocol in order to strengthen these encouraging first results on stability and reproducibility of visually guided DIBH with external optical system for respiratory monitoring. Purpose/Objective: The aim of the study was to increase total marrow irradiation (TMI) treatment effectiveness and time efficiency while minimizing the dose for non-skeletal structures. Materials and Methods: Twelve patients with multiple myeloma were treated by the following TMI method. As a target, all skeletal bones were contoured (Eclipse, Varian Inc.) excluding hand bones, jawbone, mandible and ethmoid bone. Critical organs were contoured for conformal avoidance. Due to the limitation in the longitudinal couch travel (effectively up to 135 cm), the total marrow irradiation delivery had to be split into two independent plans: HFS and FFS patient orientation. To avoid an unnecessary second CT scan, the FFS CT volume was generated by flipping the original HFS CT volume with our in-house written software. The upper body TMI plan (UTMI) covered the body from the head to 11 cm above knee joint, for which the helical tomotherapy technique was applied. The lower body TMI plan (LTMI) covered the body from the feet up to 6 cm below the knee joint, for which the direct tomotherapy technique was applied (two opposite fields of 90°-270°). All plans were implemented using the TomoHD treatment planning system (version 1.02; Accuray Inc.). The optimization goal was to achieve that a minimum of 85% of the target volume receives at least 99% of the prescription dose (12 Gy). Fractionation scheme was 3 x 4 Gy (three consecutive days, one irradiation a day). Results: In twelve patients, the following mean doses were obtained [mean±SD, Gy]: UTMI-target 12.15±0.06; LTMI-target 12.35±0.08; brain 7.64±0.32; lenses 2.24±0.28; oral cavity 4.79±0.49; lungs 7.98±0.11; heart 7.51±0.29; liver 7.91±0.40; kidneys 6.46±0.27; bowel 7.51±0.26; bladder 6.53±0.15. Mean irradiation time [mean±SD, minutes] for UTMI was 35.15±3.50, and for LTMI was 12.66±0.79 (Fig.1) .
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S339 Conclusions: Applying the described hypofractionated TMI (4 Gy dose per fraction) a dose reduction to the organs at risk ranged from 18.67%-66.48% of the prescribed dose and the effective time for one radiation session was 1 hour and 15 minutes (including patient positioning and imaging). The tomotherapy direct field angles arrangement instead of using the helical intensity-modulated radiation has allowed minimizing the delivery error associated with the setup of the leg positioning, especially in horizontal direction. An additional benefit was the shorter irradiation time. A disadvantage of the direct technique was poor conformality, as a result of which the non-skeletal structures in legs (mostly muscles and vessels) received a higher dose in order to ensure hitting the target. In conclusion, the applied 4 Gy fractionation is feasible using TomoHD system and time-efficient in a busy radiotherapy department, requiring only a single patient setup a day on three consecutive days. Through hypofractionation, the biological equivalent dose is also effectively increased. Further observation of patients treated with this scheme is necessary to evaluate the treatment response. Purpose/Objective: Data from the National Radiotherapy Implementation Group (NRIG) suggests that the provision of IMRT has improved from around 2% of patients in 2008 to around an estimated 15% in 2012 (Cooper and Williams 2012). The objective of this survey was to determine how each centre currently carries out the quality assurance (QA) processes for these IMRT treatments. For the purposes of this survey IMRT is defined as inverse planned treatments and includes linac based, Tomotherapy and Cyberknife delivery. The aim was to collect information on equipment, approach and tolerances as well as how QA approaches may change in the future. Materials and Methods: The survey was web based, however a word version was also available. Questions were divided into the following categories: Background and equipment, machine tolerance and QA, machine based verification, software based verification, future plans. Results: 57 responses were received from 53 centres (4 centres answered separately for different systems). All centres use 6MV with 27% also using 8, 10 or 15MV. 41% use dynamic delivery, 48% use step and shoot and 35% use VMAT with 11% using Tomotherapy. 82% are limiting the numbers they treat with 45% receiving extra funding for IMRT. 42% have developed their own tests for commissioning and QA. 100% perform machine based measurements to check IMRT plans with 66% measuring both point doses and dose distributions and the main burden falling on physics staff (94%). 74% perform machine based measurements for every patient, and 49% have changed their plan based on the results of the QA measurements. 63% perform software based calculations to check IMRT plans, with 88% being point doses, 3% being dose distributions only and 9% being both. However 97% have never changed a plan based on the results of the calculated IMRT check. 73% of these calculations are performed by physicists with the remaining being undertaken by dosimetrists. 87% report that they intend to change their QA processes in the near future with 41% being who does the QA, 51% changing to a different measurement, 56% reducing the number of measurements and 41% stopping doing measurements altogether.
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Conclusions: All centres currently include machine based measurements in their QA processes. This is time consuming, taking up to 30 minutes per patient, even when batched. The majority have already started looking at other techniques and the trend is towards reduction of measurements and sharing of workload. The synchrotrons used to date to accelerate light ions up to carbon are however very large and expensive. We have therefore developed efficient, compact, cost effective treatment units that can make light ions treatments available with less complexity and lower costs, for the benefit of more patients. The systems allow for five different light ions species for research and clinical use. There is promising potential in mixing light ions but to date a lack of facilities hinder such research.
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Materials and Methods:
A new compact superconducting isochronous multiple-light-ion cyclotron has been designed by Sumitomo for Hydrogen (Protons), Helium Ions, Lithium Ions, Boron and Carbon Ions. The peak energy is >300 MeV/u and the maximum Boron range is about 26 cm. (≈20cm Carbon). In mixed-modality radiation therapy it is possible to simultaneously create a uniform distribution of biological effect, dose and radiation quality in the tumor volume. For instance, with Lithium in combination with Boron or Carbon ions, the Lithium ions are mainly used in the distal tumor region whereas Boron or Carbon ions are used closer to the patient surface. By this method the low LET plateau dose from Lithium is elevated significantly by Bragg peak Boron or Carbon ion dose delivery in the shallow tumor region. Pencil Beam Scanning delivery is used exclusively for maximum dose conformity to target volumes and minimized exposure to surrounding tissues and OAR. Results: An innovative layout and arrangement of treatment rooms and the relatively compact new cyclotron accelerator allows a significant cost reduction compared to previously built carbon ion treatment facilities such as HIMAC at NIRS in Chiba, Japan, HIT in Heidelberg, Germany and CNAO in Pavia, Italy. The overall facility cost and cost per Light Ions treatment room is less than the current market prices of proton-only facilities. High dose rates from the cyclotron, fast switching and continous line scanning as opposed to synchrotrons' intermittent beam and spot scanning techniques allow for shorter irradiation times and higher patient throughput.
Conclusions:
The new light ions technology provides a compact and very efficient system for curative treatment of several common malignant tumors of:head and neck, lung, liver, prostate, bone/softtissue sarcoma, cervix, and pelvis (Tsujii 2010). At a facility cost equal or less than today's proton-only facilities, combined with enhanced throughput, the cost per treatment is reduced.
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Frameless radiosurgery: less invasive, more accurate T. Gevaert 1 , D. Verellen 1 , B. Engels 1 , M. De Ridder 1 1 Universitair Ziekenhuis Brussel, Academic Department of Radiation Oncology, Brussels, Belgium Purpose/Objective: Stereotactic radiosurgery using frame-based positioning is a well-established technique for the treatment of benign and malignant lesions. By contrast, a new trend towards frameless systems using image-guided positioning techniques is gaining mainstream acceptance. This study was designed to compare the overall accuracy of the frameless with the frame-based radiosurgery technique and to evaluate the immobilization characteristics of a commercially available frameless mask, more specifically, the setup errors and the intrafraction motion, to the invasive fixation of the frame-based technique. Materials and Methods: Multiple hidden target tests(HTT) were performed to measure the overall accuracy of the two positioning techniques for radiosurgery (i.e. frameless using stereoscopicx-ray imaging and 6DOF registration/positioning and frame-based using invasive ring and localizer box). Forty patients with 66 brain metastases were enrolled for frameless stereotactic radiosurgery using X-ray imaging and a 6DOF robotic couch. To analyze the frameless characteristics positioning results were collected before and after treatment to assess patient setup error and intrafraction motion. The obtained data was bench marked to literature for comparison with frame-based techniques.
